Bioventus Inc Cl A (BVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 35,846 | 51,238 | 42,164 | 32,910 | 22,802 |
| Receivables | 120,525 | 128,303 | 130,404 | 132,367 | 118,082 |
| Inventories | 83,187 | 82,236 | 96,273 | 96,465 | 94,045 |
| TOTAL | $249,813 | $272,842 | $280,901 | $275,203 | $249,367 |
| Non-Current Assets | |||||
| PPE Net | 21,294 | 21,899 | 22,983 | 24,512 | 25,722 |
| Investments And Advances | 2,102 | 2,293 | 2,274 | 1,687 | 1,756 |
| Intangibles | 367,121 | 375,881 | 384,860 | 394,416 | 403,193 |
| Other Non-Current Assets | 10,209 | 10,644 | 10,575 | 10,970 | 11,376 |
| TOTAL | $400,726 | $410,717 | $420,692 | $431,585 | $442,047 |
| Total Assets | $650,539 | $683,559 | $701,593 | $706,788 | $691,414 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 18,750 | 15,000 | 11,250 | 43,358 | 37,339 |
| Accounts payable and accrued liabilities | 24,050 | 10,928 | 26,649 | 24,245 | 19,197 |
| Accrued Expenses | 101,135 | 130,242 | 119,446 | 113,666 | 103,283 |
| Other current liabilities | 4,160 | 4,210 | 4,407 | 4,411 | 14,932 |
| TOTAL | $148,095 | $160,380 | $161,752 | $185,680 | $174,751 |
| Non-Current Liabilities | |||||
| Long Term Debt | 253,326 | 278,951 | 311,334 | 297,880 | 308,593 |
| Other Non-Current Liabilities | 13,452 | 12,785 | 19,615 | 19,465 | 22,669 |
| TOTAL | $268,179 | $294,732 | $332,586 | $319,809 | $331,184 |
| Total Liabilities | $416,274 | $455,112 | $494,338 | $505,489 | $505,935 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 83,535 | 83,155 | 82,763 | 82,679 | 82,144 |
| Common Shares | 84 | 83 | 83 | 83 | 82 |
| Retained earnings | -331,816 | -334,929 | -349,684 | -352,839 | -360,298 |
| Other shareholders' equity | 43,085 | 42,442 | 39,322 | 39,283 | 35,273 |
| TOTAL | $234,265 | $228,447 | $207,255 | $201,299 | $185,479 |
| Total Liabilities And Equity | $650,539 | $683,559 | $701,593 | $706,788 | $691,414 |